Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BELANTAMAB MAFODOTIN for Plasma cell myeloma refractory: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 113 adverse event reports in the FDA FAERS database where BELANTAMAB MAFODOTIN was used for Plasma cell myeloma refractory.

Most Reported Side Effects for BELANTAMAB MAFODOTIN

Side Effect Reports % Deaths Hosp.
Keratopathy 788 34.4% 181 79
Visual acuity reduced 708 30.9% 152 65
Death 499 21.8% 499 50
Plasma cell myeloma 380 16.6% 191 61
Dry eye 359 15.7% 43 31
Night blindness 317 13.8% 24 18
Photophobia 183 8.0% 12 12
Foreign body sensation in eyes 151 6.6% 9 10
Vision blurred 134 5.8% 20 17
Ocular toxicity 94 4.1% 18 5
Punctate keratitis 91 4.0% 16 10
Thrombocytopenia 90 3.9% 39 35
Visual impairment 86 3.8% 9 8
Eye disorder 75 3.3% 11 9
Corneal epithelial microcysts 74 3.2% 9 7

Other Indications for BELANTAMAB MAFODOTIN

Plasma cell myeloma (1,382) Product used for unknown indication (786) Bone lesion (9) Disease progression (6) Amyloidosis (5)

Other Drugs Used for Plasma cell myeloma refractory

DEXAMETHASONE (2,276) POMALIDOMIDE (1,562) LENALIDOMIDE (1,220) CARFILZOMIB (1,208) BORTEZOMIB (848) DARATUMUMAB (789) ISATUXIMAB (778) CYCLOPHOSPHAMIDE (518) IXAZOMIB (356) DOXORUBICIN (314)

Related Pages

BELANTAMAB MAFODOTIN Full Profile All Plasma cell myeloma refractory Drugs BELANTAMAB MAFODOTIN Demographics BELANTAMAB MAFODOTIN Timeline